VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine
The disease models are built with cells from patient donors, so they carry features of the disease itself. Drug developers can measure whether a candidate acts on those disease features in human tissue before it enters
Share
Why It Matters
VivoSim Labs is adding a new service to test if drugs work. They use real patient cells to build disease models, so drug makers can test faster.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.